MPL:ASXMedibank Private Ltd. Analysis

Medibank is trading at AUD 4.14, well below its DCF‑derived fair value of around AUD 5.31, implying roughly a 22% upside potential. The stock sits beneath its 20‑day, 50‑day and 200‑day moving averages (4.40, 4.57 and 4.82 respectively) and the 30‑day volatility is elevated at about 27.7%, indicating a bearish technical backdrop. However, the RSI of 28 signals oversold conditions and the price is hugging a key support level near AUD 4.10, which could set the stage for a short‑term bounce. On the fundamentals side, revenue is growing modestly at 5% YoY, margins are healthy, and the company generates strong free cash flow (≈ AUD 0.69 bn) with a low debt‑to‑equity ratio. The dividend yield is attractive at 4.05% but the payout ratio exceeds 100%, raising concerns about sustainability. Overall, the blend of undervalued valuation metrics, solid cash generation, and a potentially oversold price suggests a cautious but opportunistic stance for investors.
Actionable insight: Consider a modest exposure now, monitoring technical support and any regulatory developments that could affect the dividend policy, while positioning for a medium‑term rally as the market re‑prices the intrinsic value.